NSF Minority Faculty Development Workshop

Alexis Bakos, PhD, MPH, RN,CAlexis Bakos, PhD, MPH, RN,CChief, Diversity Training BranchChief, Diversity Training Branch

Center to Reduce Cancer Health Disparities, Center to Reduce Cancer Health Disparities, NCINCI

OPPORTUNITIES FOR TRAINEES TO OPPORTUNITIES FOR TRAINEES TO PROMOTE DIVERSITYPROMOTE DIVERSITY

March 23, 2010March 23, 2010

HSHS UndergradUndergrad PredoctoralPredoctoral PostdoctoralPostdoctoral Junior InvestigatorJunior Investigator

R25T: Prevention and Control Clinical Oncology

Training Grants: K12

TransitionCareer: K22

NRSA Fellowships: F31 and T32 S

Career AwardsK01 K08 K23

Cancer Center Grant: P30

SPORE: P50 TranslationalCancer Center: P30 MD/POR

R

0

1

R03

R21

Continuing Umbrella of Research Continuing Umbrella of Research ExperiencesExperiences

DiversitySupplements

Supplements to the CURE:

Career Development

Supplement Eligibility

Eligible Individuals Ethnic and/or racial minorities Socio-economically disadvantaged groups First generation college graduates Individuals with disabilities Must be US Citizen or permanent residentEligible Grants■ NCI grants

Receipt of Supplement

Applications by the NCI

■ Application Receipt: Two Cycles ■ October 1 through December 1 ■ March 1 through May 1

■ Notice of Award: Office of Grants Administration

Research Supplements to Promote Diversity in Health

Related Research

■ Available for every career level e.g. High School through Junior faculty

■ Provides up to five years of support

■ * For T32, R25T, and K12 the supplement is awarded after slots are filled

http://grants.nih.gov/grants/guide/pa-files/PA-08-190-html

Supplements to Promote Reentry into Biomedical and Behavioral Research

Careers Available for individuals who want to

reestablish active research careers Provides up to 3 years of support Period of career interruption is 1 to 8 years Candidate must have a doctoral degree Support for salary, fringe benefits, supplies

and travel

http://grants.nih.gov/grants/guide/pa-files/PA-08-191.html

Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer

Research

Mechanism: R21 (PAR-09-162) Purpose: To increase the diversity of

the research workforce by supporting investigators from diverse populations in the area of basic cancer research.

Direct Cost: $275,000 for 2 years Receipt Dates: Nov 23rd and June 23rd

Exploratory/Developmental Grants Program for Basic Cancer Research in

Cancer Health Disparities

Mechanism: R21 (PAR-09-160) Purpose: To promote basic cancer

research expertise in cancer health disparities

Direct Cost: $275,000 for 2 yrs Receipt Date: Nov 23rd and June 23rd

Basic Cancer Research in Cancer Health Disparities

Mechanism: U01 (PAR-09-161) Cooperative agreement FOA to conduct

basic research into the causes and treatment of cancer health disparities New methodologies Secondary data analyses Innovative mechanistic studies

$250,000/yr for up to 5 yrs Receipt Date: Nov 23rd and June 23rd

Office of Technology & Industrial Relations (OTIR)Innovative Technology Development for Cancer Research Mechanism R21 (RFA-CA-10-005) Feasibility studies on early stage

development (i.e., at their conceptual stage where feasibility has not been established) of cancer-relevant technologies in the area of CA biology, prevention, diagnosis, treatment, epidemiology & cancer health disparities

Up to $500,000 over 3 yr period Receipt Date: May 27 and Sept. 30, 2010

Office of Technology & Industrial Relations (OTIR)Application & Early Stage Development of Emerging Technology in Cancer Research Mechanism: R21 (RFA-CA-10-003) Feasibility studies on emerging cancer-

relevant technologies (i.e., has passed the initial development stage but hasn’t been evaluated within the context of its intended use) in the area of CA biology, prevention, diagnosis, treatment, epidemiology & cancer health disparities

Up to $275,000 direct costs over 2 yrs Receipt Date: May 27 and Sept. 30, 2010

Office of Technology & Industrial Relations (OTIR)Innovative & Early-Stage Development of Emerging Technologies in Biospecimen Science Mechanism R21 (RFA-CA-10-001) Early stage studies that develop

technologies capable of interrogating &/or maximizing the quality & utility of biospecimens

Up to $275,000 direct costs over 2 yrs Receipt Date: May 27 and Sept. 30,

2010

■ Creates a pipeline of diverse cancer investigators

■ Investigators become mentors

Manuel Penichet, M.D., Ph.D. Dr. Penichet and trainees

Example:Manuel Penichet, UCLARecipient of:*Diversity Supplement*K award *R01s

• For Supplements• Peter Ogunbiyi:

ogunbiyp@mail.nih.gov

For R21 & U01 Funding Opportunities Anil Wali: walia@mail.nih.gov

For OTIR Funding Opportunities LeeAnn Bailey: baileyl@mail.nih.gov

Main Office: 301-496-7344

DTB Contacts